AwesomeCapital

Health Catalyst prices IPO at $26

Health Catalyst (NASDAQ:HCAT) has priced its IPO of 7M common shares at $26 for total gross proceeds of $182M.

Underwriters over-allotment is an additional 1.05M common shares.

The shares are expected to begin trading today on Nasdaq under the ticker symbol “HCAT”.

Closing date is July 29.

Source: Press Release

https://seekingalpha.com/news/3481381-health-catalyst-prices-ipo-26

West Pharmaceutical EPS beats by $0.17, beats on revenue

West Pharmaceutical (NYSE:WST): Q2 Non-GAAP EPS of $0.89 beats by $0.17; GAAP EPS of $0.88 beats by $0.15.

Revenue of $469.7M (+5.0% Y/Y) beats by $9.8M.

Shares -0.39% PM.

Press Release

https://seekingalpha.com/news/3481404-west-pharmaceutical-eps-beats-0_17-beats-revenue

NovoCure EPS beats by $0.06, beats on revenue

NovoCure (NASDAQ:NVCR): Q2 GAAP EPS of -$0.01 beats by $0.06.

Revenue of $86.71M (+41.0% Y/Y) beats by $7.73M.

Press Release

https://seekingalpha.com/news/3481413-novocure-eps-beats-0_06-beats-revenue

AstraZeneca up 5% premarket on Q2 beat

AstraZeneca (AZN) Q2 results: Revenues: $5,823M (+13.0%); Product Sales: $5,718M (+13.7%); Collaboration Revenue: $105M (-16.0%).

Top-ten medicines by Product Sales: Tagrisso: $784M (+86%); Lynparza: $283M (+89%); Symbicort: $585M (-13%); Nexium: $393M (-11%); Brilinta: $389M (+23%); Farxiga: $377M (+11%); Pulmicort: $333M (+16%); Crestor: $310M (-8%); Imfinzi: $338M; Faslodex: $267M (+8%).

Net Income: $107M (-66.5%); EPS: $0.10 (-63.0%); Non-GAAP EPS: $0.73 (-27.0%); CF Ops: $491M (-754.7%).

2019 Guidance: Product Sales: An increase by a low double-digit percentage from a high single-digit percentage increase; Core EPS: $3.50 – 3.70 (unch).

Shares are up 5% premarket.

https://seekingalpha.com/news/3481447-astrazeneca-5-percent-premarket-q2-beat

Alkermes EPS beats by $0.21, beats on revenue

Alkermes (NASDAQ:ALKS): Q2 Non-GAAP EPS of $0.09 beats by $0.21; GAAP EPS of -$0.27 beats by $0.15.

Revenue of $279.87M (-8.1% Y/Y) beats by $28.47M.

Press Release

https://seekingalpha.com/news/3481480-alkermes-eps-beats-0_21-beats-

FDA accepts Epizyme’s tazemetostat application for type of soft tissue cancer

The FDA accepts for review Epizyme’s (NASDAQ:EPZM) marketing application seeking approval to use tazemetostat to treat metastatic or locally advanced epitheloid sarcoma not eligible for curative surgery. The agency’s action date is January 23, 2020.

Epitheloid sarcoma is a rare slow-growing type of soft tissue cancer that typically starts under the skin of a finger, hand, forearm, lower leg or foot.

The company will host a conference call this morning at 8:30 am to discuss the filing.

https://seekingalpha.com/news/3481490-fda-accepts-epizymes-tazemetostat-application-type-soft-tissue-cancer